{"preliminary_commentary":{"by_channel":{"x_thread":56,"podcast":34,"youtube":26},"note":"Preliminary. Indexed podcasts, YouTube videos and X posts that name this trial so far. This is where a report starts, not where it ends: the build searches for more, so finished reports usually cover more than this."},"free_build":{"available":true,"how":"POST https://www.erudio.com/api/trial-requests with {\"nct_id\": \"NCT07207824\", \"email\": \"<work email>\"}. The person who owns that inbox must confirm by the emailed link; agents cannot confirm. The result is the report's free public preview; the full report is still bought."},"commentary_summary":null,"drugs_tested":[["disitamab vedotin"]],"indication":"HER2-expressing BCG-naïve high-risk non-muscle-invasive bladder cancer","name":"HERO","nct_id":"NCT07207824","offer":{"currency":"USD","how":"Order at https://www.erudio.com/contact?report=hero-nct07207824. The price is an estimate of verified statements from the commentary indexed so far, fixed at order. Final coverage is set when the report is built. We build the report within 24 hours of confirming the order and deliver it when it passes our checks; if it cannot be built to our standard, nothing is charged.","price_usd":1950,"size":"deep","size_rule":"Deep: 301+ verified statements, estimated at 14 per indexed commentary source"},"registry":{"acronym":"HERO","arms":[{"description":"Disitamab Vedotin + BCG induction and maintenance","label":"DV + BCG","type":"EXPERIMENTAL"},{"description":"BCG induction and maintenance","label":"BCG","type":"ACTIVE_COMPARATOR"}],"collaborators":[],"completion_date":{"date":"2030-12-01","type":"ESTIMATED"},"conditions":["Bladder (Urothelial, Transitional Cell) Cancer","NMIBC"],"enrollment":{"count":182,"type":"ESTIMATED"},"has_results":false,"interventions":[{"name":"Active Comparator: BCG induction and maintenance","otherNames":[],"type":"DRUG"},{"name":"DV + BCG induction and maintenance","otherNames":[],"type":"DRUG"}],"last_update":"2026-07-21","lead_sponsor":"Fudan University","official_title":"A Phase III Randomized Controlled Trial of Disitamab Vedotin (DV) Combined With Bacillus Calmette-Guérin (BCG) in BCG-Naïve Patients With HER2-Expressing, High-Risk Non-Muscle-Invasive Bladder Cancer","overall_status":"RECRUITING","phases":["PHASE3"],"primary_completion_date":{"date":"2030-06-01","type":"ESTIMATED"},"primary_outcomes":[{"measure":"Event free survival","timeFrame":"55 months after first participant randomized"}],"references":[],"start_date":{"date":"2025-12-01","type":"ACTUAL"},"study_type":"INTERVENTIONAL","title":"DV+BCG in HER2-Expressing, BCG-Naïve High-Risk NMIBC","url":"https://clinicaltrials.gov/study/NCT07207824"},"report":null,"schema_id":"erudio.trial_listing","schema_version":"3.1","state":"listed","state_text":"No report yet. It can be ordered.","url":"https://www.erudio.com/trials/hero-nct07207824"}